Hoping for trial readout in June 2024. Recruitment going well. 11 months away!
45 boys will be in trial but only need 42 needed for readout.
Combo data expected late July early August.
LGMD Mdx date expected later in August.
RPD Voucher recently sold by Sarepta for US$102m after “conditional approval” for their Gene Therapy. ANP also has a RPD voucher which would be very attractive to any partner.
One competitor in Non Ambulant space, Fibrogen, had their P3 trial fail in June 2023.
Neuron (NEU) is the template to compare ANP to with very favourable pricing and quick uptake / sales post approval in a rare disease setting. NEU were quoting US$150k during trial but I believe is selling for US$300k now. ANP has quoted US$200k for ATL1102 during trial. What would market pricing be?? US$400k? Maybe higher. This was not mentioned on call but is my guess.
Also mentioned a few times that this will be a very attractive target for any potential partners.
Team is world class and all have experience in delivering drugs in rare paediatric diseases to market.
PTC therapeutics (PTCT) has market cap of US$3bn and sell steroids to DMD market.. approximately $600m in sales, $250m cash in bank.
ANP Price at posting:
6.5¢ Sentiment: Buy Disclosure: Held
